Case trackerEmerging

Claims for harm linked to Dupixent Updates

Updated Oct 6, 2026

If you used Dupixent and were told you have skin lymphoma, ask for a medical and legal review. The studies do not prove the drug caused your illness.

Follow the record

No source-linked updates are available here yet. The case guide has the current information and eligibility details.

Stay informed

No phone call required. We will email you about relevant court filings, settlements, or important deadlines.

ABA Model Rule 1.5: feesABA Model Rule 1.5: fees
Southern District of New York: time limitsSouthern District of New York: time limits · court
45 CFR 164.524: access to health records45 CFR 164.524: access to health records · regulator
Dupixent JPML transfer order, June 4, 2026Dupixent JPML transfer order, June 4, 2026 · court
Mandel et al: CTCL after dupilumab, 2024Mandel et al: CTCL after dupilumab, 2024 · study
Stuver et al: matched CTCL outcomes, 2024 online/2025 issueStuver et al: matched CTCL outcomes, 2024 online/2025 issue · study
FDA potential-signal table, information as of March 6, 2025FDA potential-signal table, information as of March 6, 2025 · regulator
MedlinePlus: dupilumab injection, revised August 15, 2025MedlinePlus: dupilumab injection, revised August 15, 2025 · regulator

Read the case guide for eligibility, evidence and your next steps.